Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lenaldekar (LDK) 抑制 T 细胞扩增和自身免疫性脑脊髓炎。 Lenaldekar 导致 PI3 激酶/AKT/mTOR 通路成员的去磷酸化并延迟有丝分裂晚期的敏感细胞。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,920 | 现货 | ||
10 mg | ¥ 4,320 | 现货 | ||
25 mg | ¥ 6,880 | 现货 | ||
50 mg | ¥ 9,330 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,590 | 现货 |
产品描述 | Lenaldekar (LDK) inhibits T-cell expansion and autoimmune encephalomyelitis. Lenaldekar causes dephosphorylation of members of the PI3 kinase/AKT/mTOR pathway and delays sensitive cells in late mitosis. |
体外活性 | Lenaldekar could inhibit myelin specific T cell responses through the insulin-like growth factor-1 receptor (IGF-1R) pathway. Alteration of this pathway led to marked reduction in T cell proliferation and expansion. Blocking this pathway could account for the observed decreases in clinical signs and inflammatory demyelinating disease, which was accompanied by axonal preservation[3]. |
体内活性 | Relapsing-remitting experimental autoimmune encephalomyelitis was induced through active immunization of SJL/J mice with a myelin proteolipid protein peptide. The therapeutic efficacy of Lenaldekar treatment was evaluated via daily clinical score, cross-sectional ex vivo diffusion basis spectrum imaging examination and histological analysis. Lenaldekar greatly reduced relapse severity and protected white matter integrity in these experimental autoimmune encephalomyelitis mice. Diffusion basis spectrum imaging-derived axial diffusivity, radial diffusivity and restricted diffusion tensor fraction accurately reflected axonal injury, myelin integrity and inflammation-associated cellularity change, respectively[1]. |
别名 | LDK |
分子量 | 286.33 |
分子式 | C18H14N4 |
CAS No. | 418800-15-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (192.09 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.4925 mL | 17.4624 mL | 34.9247 mL | 87.3118 mL |
5 mM | 0.6985 mL | 3.4925 mL | 6.9849 mL | 17.4624 mL | |
10 mM | 0.3492 mL | 1.7462 mL | 3.4925 mL | 8.7312 mL | |
20 mM | 0.1746 mL | 0.8731 mL | 1.7462 mL | 4.3656 mL | |
50 mM | 0.0698 mL | 0.3492 mL | 0.6985 mL | 1.7462 mL | |
100 mM | 0.0349 mL | 0.1746 mL | 0.3492 mL | 0.8731 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lenaldekar 418800-15-4 Cytoskeletal Signaling MAPK PI3K/Akt/mTOR signaling Tyrosine Kinase/Adaptors Akt IGF-1R S6 Kinase LDK Inhibitor inhibitor inhibit